NASDAQ:TYME

Tyme Technologies Stock Forecast, Price & News

$1.53
-0.12 (-7.27 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.53
Now: $1.53
$1.64
50-Day Range
$1.65
MA: $1.94
$2.48
52-Week Range
$0.85
Now: $1.53
$4.99
Volume2.26 million shs
Average Volume10.49 million shs
Market Capitalization$199.55 million
P/E RatioN/A
Dividend YieldN/A
Beta0.94
Tyme Technologies, Inc., a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-18, a CMBT compound that is in preclinical stage for the treatment of solid tumors. Tyme Technologies, Inc. has a research collaboration with NYU Langone Health to advance the development of treatments for patients with metastatic cancers, including pancreatic cancer, as well as with Mayo Clinic; and a strategic collaboration with Eagle Pharmaceuticals, Inc. to advance oral SM-88 for the treatment of patients with cancer. The company was formerly known as Global Group Enterprises Corp. Tyme Technologies, Inc. was founded in 2011 and is headquartered in New York, New York.
Tyme Technologies logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TYME
CUSIPN/A
Phone212-461-2315
Employees18
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.15 per share

Profitability

Net Income$-22,000,000.00

Miscellaneous

Market Cap$199.55 million
Next Earnings Date5/19/2021 (Estimated)
OptionableOptionable

Headlines

Tyme: Undercovered Growth Story In Pancreatic Cancer
March 6, 2021 |  seekingalpha.com
Why Tyme Technologies Stock Is Taking Off Today
February 9, 2021 |  finance.yahoo.com
Why Tyme Stock Got Demolished Today
February 4, 2021 |  finance.yahoo.com
Tyme Technologies Shares Dive On $100M Equity Offering
February 4, 2021 |  markets.businessinsider.com
See More Headlines

MarketRank

Overall MarketRank

1.31 out of 5 stars

Medical Sector

802nd out of 2,016 stocks

Pharmaceutical Preparations Industry

388th out of 771 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$1.53
-0.12 (-7.27 %)
(As of 04/12/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TYME News and Ratings via Email

Sign-up to receive the latest news and ratings for TYME and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Tyme Technologies (NASDAQ:TYME) Frequently Asked Questions

Is Tyme Technologies a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tyme Technologies in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Tyme Technologies stock.
View analyst ratings for Tyme Technologies
or view top-rated stocks.

What stocks does MarketBeat like better than Tyme Technologies?

Wall Street analysts have given Tyme Technologies a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Tyme Technologies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Tyme Technologies?

Tyme Technologies saw a drop in short interest in February. As of February 26th, there was short interest totaling 3,030,000 shares, a drop of 26.1% from the February 11th total of 4,100,000 shares. Based on an average daily trading volume, of 10,330,000 shares, the short-interest ratio is presently 0.3 days. Approximately 3.6% of the shares of the company are short sold.
View Tyme Technologies' Short Interest
.

When is Tyme Technologies' next earnings date?

Tyme Technologies is scheduled to release its next quarterly earnings announcement on Wednesday, May 19th 2021.
View our earnings forecast for Tyme Technologies
.

How were Tyme Technologies' earnings last quarter?

Tyme Technologies, Inc. (NASDAQ:TYME) issued its quarterly earnings results on Thursday, February, 4th. The company reported ($0.05) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.02.
View Tyme Technologies' earnings history
.

How has Tyme Technologies' stock price been impacted by COVID-19 (Coronavirus)?

Tyme Technologies' stock was trading at $1.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TYME shares have increased by 45.7% and is now trading at $1.53.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for TYME?

2 equities research analysts have issued 1 year price objectives for Tyme Technologies' stock. Their forecasts range from $9.50 to $9.50. On average, they expect Tyme Technologies' stock price to reach $9.50 in the next year. This suggests a possible upside of 520.9% from the stock's current price.
View analysts' price targets for Tyme Technologies
or view top-rated stocks among Wall Street analysts.

Who are Tyme Technologies' key executives?

Tyme Technologies' management team includes the following people:
  • Mr. Steven E. Hoffman, Co-Founder, Chairman & Chief Science Officer (Age 58, Pay $900.79k)
  • Mr. Richard Cunningham, CEO & Director (Age 50)
  • Ms. Barbara C. Galaini, Acting Principal Financial Officer, Principal Accounting Officer & Corp. Controller (Age 63)
  • Mr. James Biehl J.D., Chief Legal Officer & Sec. (Age 57)
  • Dr. Giuseppe Del Priore, Chief Medical Officer (Age 59)
  • Dr. Jonathan M. Eckard, Chief Bus. Officer (Age 47)
  • Mr. John Zucaro P.E., Sr. VP of CMC
  • Dr. John M. Rothman, Exec. VP of Product Devel. (Age 73)

Who are some of Tyme Technologies' key competitors?

What other stocks do shareholders of Tyme Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tyme Technologies investors own include Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Vaxart (VXRT), Allena Pharmaceuticals (ALNA), OpGen (OPGN), Selecta Biosciences (SELB), MEI Pharma (MEIP), Pfizer (PFE) and SCYNEXIS (SCYX).

What is Tyme Technologies' stock symbol?

Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME."

How do I buy shares of Tyme Technologies?

Shares of TYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tyme Technologies' stock price today?

One share of TYME stock can currently be purchased for approximately $1.53.

How much money does Tyme Technologies make?

Tyme Technologies has a market capitalization of $199.55 million. The company earns $-22,000,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis.

How many employees does Tyme Technologies have?

Tyme Technologies employs 18 workers across the globe.

What is Tyme Technologies' official website?

The official website for Tyme Technologies is www.tymeinc.com.

Where are Tyme Technologies' headquarters?

Tyme Technologies is headquartered at 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004.

How can I contact Tyme Technologies?

Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-461-2315 or via email at [email protected]


This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.